





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	D. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO.		CONFIRMATION NO.	
09/847,945	05/02/2001	Neil P. Desai	AB11460-3 (071243-1317)	6174
7	2590 02/25/2002			
Stephen E. Re	eiter	EXAMINER		
FOLEY & LA	RDNER	DEWITTY, ROBERT M		
23rd Floor				
402 West Broa	dway			-
San Diego, CA 92101-3542			ART UNIT	PAPER NUMBER
			1616	
			DATE MAILED: 02/25/2002	6

Please find below and/or attached an Office communication concerning this application or proceeding.

• ·		1						
Office Action Summary		Application No.	<u> </u>	Applicant(s)				
		09/847,945		DESAI ET AL				
		Examiner		Art Unit				
		Robert M DeWitty	h - 4:4h 4h - 4	1616				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
1)	Responsive to communication(s) filed on	·						
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ Th	nis action is non-fin	al.					
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)🛛	Claim(s) $1-30$ is/are pending in the application	n.						
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) 🗌	Claim(s) is/are allowed.							
6)🛛	Claim(s) <u>1-30</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)	Claim(s) are subject to restriction and/c	or election requirem	nent.					
Application	on Papers							
9)□ T	he specification is objected to by the Examine	er.						
10)□ T	he drawing(s) filed on is/are: a) 🗌 acce	pted or b) Objecte	d to by the Exa	miner.				
	Applicant may not request that any objection to the	ne drawing(s) be held	in abeyance. So	ee 37 CFR 1.85(a).				
11)[ T	he proposed drawing correction filed on	_ is: a)∏ approved	d b)  disappro	ved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) All b) Some * c) None of:								
1. Certified copies of the priority documents have been received.								
2. Certified copies of the priority documents have been received in Application No								
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲		/ (PTO-413) Paper No(s) Patent Application (PTO-				

Application/Control Number: 09/847,945

Art Unit: 1616

## **DETAILED ACTION**

Claims 1-30 are pending in the instant application.

## **Priority**

1. This application repeats a substantial portion of prior Application No. 09/446,783, filed May 16, 2000, which in turn claims priority from PCT Application No. US98/12372, and adds and claims additional disclosure not presented in the prior application. Since this application names an inventor or inventors named in the prior application, it may constitute a continuation-in-part of the prior application. Should applicant desire to obtain the benefit of the filing date of the prior application, attention is directed to 35 U.S.C. 120 and 37 CFR 1.78.

## Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1 and 2 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, claim 2 contains the limitation that the drug is in nanoparticle form, however it is unclear what "nanoparticle" refers to.

Claim Rejections - 35 USC § 103

Application/Control Number: 09/847,945

Art Unit: 1616

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 1-30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hunter et al. (U.S. Pat. No. 6,333,347) further in view of Dorland's Illustrated Medical Dictionary.

Hunter teaches methods and compositions for intra-pericardial administration of anti-microtubule agents suitable for use in treating or preventing a variety of diseases of the pericardium, heart or coronary vasculature (Abstract). The compositions may contain an anti-microtuble agent formulated with other compounds. Paclitaxel is an example of a useful anti-microtuble agent, and gelatin or albumin are examples of suitable compounds to be formulated with the anti-microtuble agent (col. 1, line 45-col. 2, line 30). Stenosis, and restenosis are examples of diseases prevented or treated by Hunter's compositions (col. 3, lines 16-19).

In an example, microparticles of paclitaxel and an additive (wherein such additive can be gelatin or albumin) were prepared. Release rate studies were performed on the microparticles (see Example 4, start col. 14, line 1).

The therapeutic compositions may be fashioned in any size ranging from 50 nm to 500 μm (col. 9, line 35-37). When used in the treatment of restenosis, treatment may be made before, during or after ballon angioplasty or stenting (col. 10, lines 20-22). In one embodiment, treatment may be made trans-myocardially (col. 10, lines 42-44).

Application/Control Number: 09/847,945

Art Unit: 1616

Page 4

Hunter does not explicitly disclose treating hyperplasia, however hyperplasia, as defined by Dorlands Medical Dictionary, is defined as "the abnormal multiplication or increase in the number of normal cells in normal arrangement in a tissue". As the instant specification defines restenosis as "the result of the normal healing response which involves proliferation of smooth muscle cells as well as migration of smooth muscle cells into the area of vascular injury", it is understood by the examiner that restenosis is a species of hyperplasia. Thus, Hunter makes obvious the use of the taught compositions in the treatment of hyperplasia.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert M DeWitty whose telephone number is 703-308-2411. The examiner can normally be reached on 9:00am - 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees can be reached on 703-308-4527. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-7924 for regular communications and 703-308-7924 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-

1235.

**RMD** 

February 21, 2002

JOSE' G. DEES SUPERVISORY PATENT EXAMINER